Clinical data, including drug treatment and localisation of tissue samples, of cases analysed in the study
| Patient No | Age (y) | Sex | Duration of disease (y) | Localisation | Therapy |
| CD1 | 27 | M | 13 | Descending colon | Prednisolone |
| CD2 | 35 | F | 14 | Sigmoid colon | Mesalazine |
| CD3 | 59 | M | 7 | Ascending colon | Prednisolone |
| CD4 | 37 | F | 8 | Transverse colon | Prednisolone |
| CD5 | 49 | F | 5 | Ascending colon | Mesalazine |
| CD6 | 46 | M | 11 | Ascending colon | Prednisolone |
| CD7 | 25 | M | 5 | Ascending colon | Budenoside/mesalazine |
| CD8 | 18 | M | 9 | Ascending colon | Budenoside/mesalazine |
| CD9 | 36 | M | 5 | Rectum | Mesalazine |
| CD10 | 34 | M | 2 | Ascending colon | None |
| UC1 | 46 | F | 22 | Transverse colon | 5-ASA |
| UC2 | 26 | F | 9 | Sigmoid colon | 5-ASA/prednisolone |
| UC3 | 55 | M | 11 | Rectum | 5-ASA/prednisolone |
| UC4 | 35 | M | 11 | Sigmoid colon | Prednisolone |
| UC5 | 62 | M | 8 | Transverse colon | 5-ASA/prednisolone |
CD, Crohn's disease; UC, ulcerative colitis; 5-ASA, 5-aminosalicylic acid.